Cargando…
Combination therapies for MPNSTs targeting RABL6A-RB1 signaling
Precision medicine relies on a detailed molecular understanding of disease pathogenesis. Here, we consider urgently needed therapeutic options for malignant peripheral nerve sheath tumors (MPNSTs) based on emerging insights into druggable pathway alterations found to drive this deadly cancer. Recent...
Autores principales: | Kohlmeyer, Jordan L., Gordon, David J., Tanas, Munir R., Dodd, Rebecca D., Monga, Varun, Darbro, Benjamin W., Quelle, Dawn E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800773/ https://www.ncbi.nlm.nih.gov/pubmed/33456709 http://dx.doi.org/10.18632/oncotarget.27862 |
Ejemplares similares
-
RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner
por: Kohlmeyer, Jordan L., et al.
Publicado: (2021) -
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
por: Kohlmeyer, Jordan L, et al.
Publicado: (2022) -
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
por: Kohlmeyer, Jordan L, et al.
Publicado: (2020) -
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas
por: Desai, Chandni, et al.
Publicado: (2021) -
RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo
por: Maharjan, Chandra K., et al.
Publicado: (2021)